Overview

Phase I Study of IPI-504 and Docetaxel in Patients With Advanced Solid Tumors

Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
This study is a Phase I clinical trial of IPI-504 in combination with docetaxel (Taxotere).The purposes of the study are to determine: - the safety profile, - the highest dose of IPI-504 that can be given with docetaxel without causing severe side effects, and - to recommend a Phase II dose of the combination in patients with solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Infinity Pharmaceuticals, Inc.
Treatments:
Docetaxel